November 18, 2021 -- Bristol-Myers Squibb (BMS) has given its 2021 Golden Ticket awards to five startup biotechnology companies in recognition of their pursuit of research in novel target identification, drug delivery, discovery technology platforms, or translational R&D in a variety of therapeutic research fields.
The winners are as follows:
- RADD Pharmaceuticals (LabCentral, Cambridge, MA), a startup focused on previously undrugged cancer targets
- Rubik Therapeutics (LabCentral, Cambridge, MA), a company developing engineered cell therapies for solid tumors by leveraging its data-driven discovery platforms
- Waypoint Bio (BioLabs, New York, NY), a startup working to develop novel approaches to treat dosage-sensitive diseases using its genomics and machine-learning platform for high-throughput screening that can extract high-dimensional multiplexed cellular features
- Altay Therapeutics, a preclinical-stage drug discovery company that is working to develop therapies by targeting disease-causing transcription factors
- VastBiome (MBC BioLabs, San Francisco, CA), a DNA-first drug discovery company mapping the human gut microbiome to make medicines
The winners receive one year of fully equipped, permitted, and supported lab space for biomedical research, plus programming and networking opportunities to help advance their science and build their companies, BMS said.
BMS launched its Golden Ticket program in 2016.
Copyright © 2021 scienceboard.net